Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzàlez U, Castel T, Campoy A, Herrero J, Martí R, Brunet-Vidal J, Milà M. Puig S, et al. Among authors: marti r. J Clin Oncol. 2005 May 1;23(13):3043-51. doi: 10.1200/JCO.2005.08.034. J Clin Oncol. 2005. PMID: 15860862
Seborrheic keratosislike melanoma with folliculotropism.
Carrera C, Segura S, Palou J, Puig S, Segura J, Martí RM, Malvehy J. Carrera C, et al. Arch Dermatol. 2007 Mar;143(3):373-6. doi: 10.1001/archderm.143.3.373. Arch Dermatol. 2007. PMID: 17372102
Temozolomide as prophylaxis for melanoma brain metastases.
Conill C, González-Cao M, Jorcano S, Puig S, Malvehy J, Martí R, Castel T. Conill C, et al. Among authors: marti r. Melanoma Res. 2004 Feb;14(1):73-4. doi: 10.1097/00008390-200402000-00012. Melanoma Res. 2004. PMID: 15091198 Clinical Trial. No abstract available.
Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.
Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de-Paillerets BB. Goldstein AM, et al. Among authors: marti r. Int J Cancer. 2007 Aug 15;121(4):825-31. doi: 10.1002/ijc.22712. Int J Cancer. 2007. PMID: 17397031 Free article.
Melanoma incidence increases in the elderly of Catalonia but not in the younger population: effect of prevention or consequence of immigration?
Puig S, Marcoval J, Paradelo C, Azon A, Bartralot R, Bel S, Bigata X, Boada A, Campoy A, Carrera C, Curco N, Dalmau J, Ferrándiz C, Ferreres JR, Formigon M, Gallardo F, Gonzalez A, Just M, Llistosella E, Marti RM, Nogues ME, Pedragosa R, Pujol JA, Roldán-Marín R, Sabat M, Salleras M, Smandia JA, Zaballos P, Plana E, Malvehy J. Puig S, et al. Among authors: marti rm. Acta Derm Venereol. 2015 Apr;95(4):422-6. doi: 10.2340/00015555-1997. Acta Derm Venereol. 2015. PMID: 25367888 Free PMC article.
Small cell melanoma and ulceration as predictors of positive sentinel lymph node in malignant melanoma patients.
Cuéllar FA, Vilalta A, Rull R, Vidal-Sicart S, Palou J, Ventura PJ, Pous E, Quinto L, Malvehy J, Martí R, Puig S, Vilella R, Soler J, Benítez D, Yachi E, Lecha M, Pons F, Conill C, Visa J, Castel T; Malignant Melanoma Group. Cuéllar FA, et al. Among authors: marti r. Melanoma Res. 2004 Aug;14(4):277-82. doi: 10.1097/01.cmr.0000136712.82910.a1. Melanoma Res. 2004. PMID: 15305158
Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
Vilella R, Benítez D, Milà J, Lozano M, Vilana R, Pomes J, Tomas X, Costa J, Vilalta A, Malvehy J, Puig S, Mellado B, Martí R, Castel T. Vilella R, et al. Among authors: marti r. Cancer Immunol Immunother. 2004 Jul;53(7):651-8. doi: 10.1007/s00262-003-0495-3. Epub 2004 Mar 16. Cancer Immunol Immunother. 2004. PMID: 14999431 Free PMC article. Clinical Trial.
680 results